A Study of IDP-001 in Advanced or Metastatic Solid Tumors
A Phase 1/2 Open-label Study of IDP-001 in Advanced or Metastatic Squamous Cell Lung Cancer and Other Solid Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: InduPro Inc.
- Phone Number: 617-798-1770
- Email: clinicaltrials@induprotx.com
Study Locations
-
-
California
-
Los Angeles, California, United States, 90025
- Recruiting
- START Los Angeles
-
Contact:
- Email: hopeteam@startresearch.com
-
Principal Investigator:
- Navid Hafez, M.D.
-
-
Florida
-
Sarasota, Florida, United States, 34232
- Recruiting
- Florida Cancer Specialists
-
Contact:
- Phone Number: 941-377-9993
- Email: clinicaltrials@flcancer.com
-
Principal Investigator:
- Manish Patel, M.D.
-
-
Indiana
-
Indianapolis, Indiana, United States, 46250
- Recruiting
- Community Cancer Center North
-
Contact:
- Adam Norris
- Phone Number: 317-621-3858
- Email: anorris@ecommunity.com
-
Principal Investigator:
- Nikhil Shukla, M.D.
-
-
New York
-
Buffalo, New York, United States, 14263
- Recruiting
- Roswell Park Cancer Institute
-
Principal Investigator:
- Prantesh Jain, M.D.
-
Contact:
- Phone Number: 1-800-767-9355
- Email: AskRoswell@RoswellPark.org
-
Lake Success, New York, United States, 11042
- Recruiting
- START New York Long Island
-
Contact:
- Email: hopeteam@startresearch.com
-
Principal Investigator:
- Geraldine O'Sullivan-Coyne, M.D.
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- Recruiting
- START Dallas Forth Worth
-
Contact:
- Email: hopeteam@startresearch.com
-
Principal Investigator:
- Salwan Al-Mutar, M.D.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Histologically-confirmed advanced, metastatic, or recurrent solid tumors that is not amenable to surgical resection or other approved therapeutic options
- Satisfy requirements for prior treatments per tumor type as outlined in the protocol
- Measurable disease per RECIST v1.1
- Participant willing to provide tumor biopsies
- Adequate organ function
- Agree to contraception requirements as outlined in the protocol
- Life expectancy greater than 12 weeks
Exclusion Criteria:
- Any clinically significant cardiac disease
- Any clinically significant corneal disorder
- Known, active, and uncontrolled hepatitis B virus (HBV), hepatitis virus (HCV) or human immunodeficiency virus (HIV), or uncontrolled chronic or ongoing infectious requiring intravenous treatment.
- Active significant neurologic disorders
- Requires home oxygen
- Active autoimmune disease
- History or active skin disease requiring frequent treatment
- History of major immunologic reaction to prior immunoglobulin G-containing agent
- Clinically significant ascites or liver disease
- Uncontrolled diabetes or diabetic neuropathy
- Active bleeding disorders
- Participation in a concurrent clinical study in the treatment period
- Pregnant or lactating or planning to become pregnant
- Known hypersensitivity to IDP-001 or any of its ingredients
- Unresolved toxicities from previous anticancer therapy
- Has had a seizure prior to Screening
- Prior solid organ transplant or allogeneic stem cell transplant
- Current endocrinopathy
- History of Stevens-Johnson syndrome or Toxic Epidermal Necrolysis
- History or interstitial lung disease (ILD) or pneumonitis requiring treatment with systemic steroids
- Stroke or transient ischemic attack prior to Screening
- Participant has any other condition or illness that, in the opinion of the Investigator, may compromise participant safety, compliance, or interfere with the conduct and evaluation of the current study.
Note: Other inclusion and exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Phase 1 Part 1 Dose Escalation
Participants with advanced or metastatic solid tumors will receive IDP-001 as intravenous (IV) infusion.
|
IV infusion
|
|
Experimental: Phase 1 Part 2 Indication Selection
Participants with a single tumor indication will receive IDP-001 as IV infusion
|
IV infusion
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Phase 1 Part 1: Number of Participants with Dose Limiting Toxicities (DLTs) during Cycle 1
Time Frame: 3 weeks
|
3 weeks
|
|
Phase 1 Part 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Dose Reduction, Dose Interruption, and Dose Discontinuation
Time Frame: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator
Time Frame: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Duration of Response (DOR) per RECIST Version 1.1 as Assessed by Investigator
Time Frame: Approximately 6 months
|
Approximately 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Area Under the Concentration Time Curve (AUC) of IDP-001
Time Frame: Approximately 6 months
|
Approximately 6 months
|
|
Maximum Observed Plasma Concentration (Cmax) of IDP-001
Time Frame: Approximately 6 months
|
Approximately 6 months
|
|
Number of Participants with Anti-drug Antibodies (ADAs) in Blood
Time Frame: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 1: ORR per RECIST Version 1.1 as Assessed by Investigator
Time Frame: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 1: DOR per RECIST Version 1.1 as Assessed by Investigator
Time Frame: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Dose Reduction, Dose Interruption, and Dose Discontinuation
Time Frame: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Disease Control Rate (DCR) per RECIST Version 1.1 as Assessed by Investigator
Time Frame: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Time to Response (TTR) per RECIST Version 1.1 as Assessed by Investigator
Time Frame: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Progression Free Survival (PFS) per RECIST Version 1.1 as Assessed by Investigator
Time Frame: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Overall Survival (OS)
Time Frame: Approximately 18 months
|
Approximately 18 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Site
- Neoplasms
- Intestinal Diseases
- Neoplasms by Histologic Type
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Colorectal Neoplasms
- Intestinal Neoplasms
- Rectal Diseases
- Head and Neck Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplastic Processes
- Esophageal Diseases
- Carcinoma
- Neoplasms, Squamous Cell
- Esophageal Neoplasms
- Anus Diseases
- Rectal Neoplasms
- Pathological Conditions, Signs and Symptoms
- Squamous Cell Carcinoma of Head and Neck
- Esophageal Squamous Cell Carcinoma
- Carcinoma, Squamous Cell
- Neoplasm Metastasis
- Anus Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- IDP-001-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.